Merck Secures FDA Approval for Welireg in Renal Cell Carcinoma
Merck (NYSE:MRK) has secured FDA approval for Welireg in combination with Lenvima for certain previously treated adults with advanced renal cell carcinoma. This marks a significant milestone for the company's oncology pipeline. The new indication pairs belzutifan, sold as Welireg, with lenvatinib, sold as Lenvima, for adults with advanced renal cell carcinoma that has a clear cell component and who have already received prior therapy.
The approval strengthens Merck's position in genitourinary cancers, an area where the company already markets its flagship anti-PD-1 antibody Keytruda in combination regimens. The deal also reflects a strategy of building franchises through complementary mechanisms rather than relying on a single product.
Additionally, Merck has entered into an exclusive global license agreement with SciBrunch Therapeutics for SPR-twenty-fifteen, an investigational oral inhibitor of a mutated form of KRAS. This move adds an option in a field where scientific momentum is strong, although the path from license to approval is long and uncertain.
The company also disclosed that it and its partner Daiichi Sankyo voluntarily withdrew a United States biologics license application for ifinatamab deruxtecan after discussions with the agency indicated that data from a mid-stage lung cancer study did not satisfy the requirements for the proposed accelerated pathway. This setback is unlikely to alter the overall shape of Merck's oncology business.